A Phase 2 interventional study of AKB-6548 and Placebo in Anemia and Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 47 sites in United States. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 3rd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 82 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2013.
This study's enrollment of 210 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 9 in phase 2, and was the 3rd registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AKB-6548
Drug: Placebo
Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Percentage of Participants Achieving a Successful Hemoglobin Response
Hemoglobin (Hgb) response was defined as participants with mean Hgb ≥11.0 grams per deciliter (g/dL) (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving Erythropoiesis-Stimulating Agents (ESA) or transfusion.
Time frame: Weeks 19 and 20
Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study
Participants who have experienced an excursion in Hgb to ≥13.0 g/dL at any time during the study were considered as "failures". Data was presented for failures.
Time frame: Up to 20 Weeks
Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing). Analysis of this secondary outcome measure is a reanalysis of the primary outcome measure whereby the response was determined solely by the Hgb value and receiving rescue therapy did not make the participant a failure.
Time frame: Weeks 19 and 20
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Treatment Naïve group, defined as participants who had never received treatment with an ESA and who had a screening Hgb level of ≤10.5 g/dL.
Time frame: Weeks 19 and 20
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Previously Treated group, defined as participants who had previously received ≥1 dose of an ESA, had been off of ESA therapy for ≥11 weeks at the time of screening, and had a screening Hgb level of ≤10.5 g/dL.
Time frame: Weeks 19 and 20
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Actively Treated group, defined as participants who had been actively treated with an ESA for a minimum of 4 months before screening, had received at least 2 doses within the last 4 months, had received their last dose within 6 weeks before screening, and had a screening Hgb level ≥9.5 g/dL and ≤12.0 g/dL.
Time frame: Weeks 19 and 20
Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Analysis of this secondary outcome measure was performed in the mITT population.
Time frame: Weeks 19 and 20
Change From Baseline in Hemoglobin
Blood samples were collected to assess Hgb. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hgb concentration increased.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Absolute Values of Hemoglobin
Blood samples were collected at indicated time points for analysis of hemoglobin
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Change From Baseline in Hematocrit
Blood samples were collected to assess Hematocrit. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hematocrit concentration increased.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Absolute Values of Hematocrit
Blood samples were collected at indicated time points for analysis of Hematocrit.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Change From Baseline in Red Blood Cell Count
Blood samples were collected to assess red blood cell count. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated red blood cell count increased.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Absolute Values of Red Blood Cell Count
Blood samples were collected at indicated time points for analysis of red blood cell count.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Change From Baseline in Reticulocyte Count
Blood samples were collected to assess reticulocyte count. Baseline was defined as mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated reticulocyte count increased.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Absolute Values of Reticulocyte Count
Blood samples were collected at indicated time points for analysis of reticulocyte count.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Percentage of Participants Who Received ESA Rescue
Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
Time frame: Up to 20 Weeks
Mean Number of ESA Rescue Doses Administered Per Participant
Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
Time frame: Up to 20 Weeks
Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue
Participants were administered packed red blood cell transfusion as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia
Time frame: Up to 20 Weeks
Number of Packed Red Blood Cell Transfusion Administered Per Participant
Participants were administered packed red blood cells as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
Time frame: Up to 20 Weeks
Time to First Transfusion or ESA Rescue Medication Intake
Rescue therapy was defined as red blood cell transfusion or ESA administration in participants meeting Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
Time frame: Up to 20 Weeks
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)
An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.
Time frame: Up to 20 Weeks
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology, serum chemistry, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to 20 Weeks
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to 20 Weeks
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
Time frame: Up to 20 Weeks
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
A Baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to 20 Weeks
Exploratory: Change From Baseline in Iron and Total Iron Binding Capacity (TIBC)
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Transferrin
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Transferrin Saturation
Time frame: Baseline and up to Week 20
Exploratory: Mean Weekly Dose of Intravenous Elemental Iron Administered
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Iron and Total Iron Binding Capacity (TIBC)
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Transferrin
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Transferrin Saturation
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Reticulocyte Hemoglobin Content
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Reticulocyte Hemoglobin Content
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Hemoglobin A1c
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Hemoglobin A1c
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Lipids
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Lipids
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Hepcidin
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Hepcidin
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Time frame: Baseline and up to Week 20
Exploratory: Absolute Values of Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin
Time frame: Baseline and up to Week 20
Exploratory: Change From Baseline in Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin
Time frame: Baseline and up to Week 20
Exploratory: Neurocognitive Functioning as a Measure
Time frame: Baseline and up to Week 20
Exploratory: Patient-Reported Outcome Measures
Time frame: Baseline and up to Week 20
Exploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites
Time frame: Baseline and up to Week 20
Exploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites
Time frame: Baseline
| Milestone | Vadadustat | Placebo |
|---|---|---|
| Started | 138 | 72 |
| Completed | 112 | 63 |
| Not completed | 26 | 9 |
| Withdrew: Adverse event | 10 | 3 |
| Withdrew: Worsening of ckd | 6 | 4 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Worsening of anemia | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Non- compliance | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Other | 1 | 0 |
Hemoglobin (Hgb) response was defined as participants with mean Hgb ≥11.0 grams per deciliter (g/dL) (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving Erythropoiesis-Stimulating Agents (ESA) or transfusion.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response | 54.9 | 10.3 |
Participants who have experienced an excursion in Hgb to ≥13.0 g/dL at any time during the study were considered as "failures". Data was presented for failures.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study | 59.6 | 88.9 |
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing). Analysis of this secondary outcome measure is a reanalysis of the primary outcome measure whereby the response was determined solely by the Hgb value and receiving rescue therapy did not make the participant a failure.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value | 44.9 | 13.9 |
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Treatment Naïve group, defined as participants who had never received treatment with an ESA and who had a screening Hgb level of ≤10.5 g/dL.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group | 50 | 7.9 |
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Previously Treated group, defined as participants who had previously received ≥1 dose of an ESA, had been off of ESA therapy for ≥11 weeks at the time of screening, and had a screening Hgb level of ≤10.5 g/dL.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group | 41.5 | 19 |
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Actively Treated group, defined as participants who had been actively treated with an ESA for a minimum of 4 months before screening, had received at least 2 doses within the last 4 months, had received their last dose within 6 weeks before screening, and had a screening Hgb level ≥9.5 g/dL and ≤12.0 g/dL.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group | 33.3 | 7.7 |
Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Analysis of this secondary outcome measure was performed in the mITT population.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population | 44.1 | 11.1 |
Blood samples were collected to assess Hgb. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hgb concentration increased.
| g/dL | Vadadustat | Placebo |
|---|---|---|
| Baseline | 9.94 ± 0.861 | 9.96 ± 0.790 |
| Week 2 | 0.1 ± 0.756 | -0.22 ± 0.564 |
| Week 4 | 0.39 ± 0.868 | -0.25 ± 0.679 |
| Week 6 | 0.63 ± 1.059 | -0.41 ± 0.835 |
| Week 8 | 0.69 ± 1.087 | -0.4 ± 0.878 |
| Week 12 | 0.9 ± 1.066 | -0.2 ± 0.864 |
| Week 16 | 0.76 ± 1.055 | -0.18 ± 0.963 |
| Week 19 | 0.73 ± 1.063 | -0.16 ± 0.926 |
| Week 20 | 0.88 ± 1.161 | -0.08 ± 0.933 |
Blood samples were collected at indicated time points for analysis of hemoglobin
| g/dL | Vadadustat | Placebo |
|---|---|---|
| Baseline | 9.94 ± 0.861 | 9.96 ± 0.79 |
| Week 2 | 10.02 ± 0.909 | 9.74 ± 0.714 |
| Week 4 | 10.35 ± 0.979 | 9.7 ± 0.733 |
| Week 6 | 10.61 ± 0.996 | 9.6 ± 0.758 |
| Week 8 | 10.66 ± 0.987 | 9.6 ± 0.848 |
| Week 12 | 10.87 ± 0.958 | 9.82 ± 0.682 |
| Week 16 | 10.79 ± 0.895 | 9.83 ± 0.841 |
| Week 19 | 10.74 ± 0.881 | 9.93 ± 0.897 |
| Week 20 | 10.88 ± 1.002 | 9.93 ± 0.859 |
Blood samples were collected to assess Hematocrit. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hematocrit concentration increased.
| Percentage of red blood cells in blood | Vadadustat | Placebo |
|---|---|---|
| Baseline | 30.4 ± 2.96 | 30.3 ± 2.90 |
| Week 2 | 0.8 ± 2.46 | -0.6 ± 1.97 |
| Week 4 | 2 ± 2.87 | -0.5 ± 2.33 |
| Week 6 | 2.5 ± 3.55 | -1 ± 2.87 |
| Week 8 | 2.7 ± 3.44 | -1 ± 3.15 |
| Week 12 | 3 ± 3.5 | -0.3 ± 2.95 |
| Week 16 | 3.3 ± 3.48 | -0.1 ± 3.24 |
| Week 19 | 3.1 ± 3.51 | 0 ± 3.19 |
| Week 20 | 3 ± 3.8 | 0.1 ± 3.13 |
Blood samples were collected at indicated time points for analysis of Hematocrit.
| Percentage of red blood cells in blood | Vadadustat | Placebo |
|---|---|---|
| Baseline | 30.4 ± 2.96 | 30.3 ± 2.9 |
| Week 2 | 31.2 ± 3.06 | 29.7 ± 2.62 |
| Week 4 | 32.4 ± 3.17 | 29.7 ± 2.72 |
| Week 6 | 33.1 ± 3.21 | 29.4 ± 2.46 |
| Week 8 | 33.2 ± 3.05 | 29.3 ± 3.05 |
| Week 12 | 33.5 ± 3.19 | 30.2 ± 2.05 |
| Week 16 | 34 ± 3.02 | 30.3 ± 2.87 |
| Week 19 | 33.7 ± 2.83 | 30.7 ± 2.83 |
| Week 20 | 33.6 ± 3.19 | 30.4 ± 2.7 |
Blood samples were collected to assess red blood cell count. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated red blood cell count increased.
| 10^6 cells per microliter | Vadadustat | Placebo |
|---|---|---|
| Baseline | 3.38 ± 0.402 | 3.34 ± 0.322 |
| Week 2 | 0.02 ± 0.243 | -0.08 ± 0.212 |
| Week 4 | 0.12 ± 0.277 | -0.08 ± 0.222 |
| Week 6 | 0.18 ± 0.346 | -0.14 ± 0.276 |
| Week 8 | 0.23 ± 0.351 | -0.14 ± 0.32 |
| Week 12 | 0.3 ± 0.357 | -0.08 ± 0.29 |
| Week 16 | 0.28 ± 0.363 | -0.06 ± 0.331 |
| Week 19 | 0.26 ± 0.374 | -0.04 ± 0.319 |
| Week 20 | 0.3 ± 0.411 | -0.01 ± 0.314 |
Blood samples were collected at indicated time points for analysis of red blood cell count.
| 10^6 cells per microliter | Vadadustat | Placebo |
|---|---|---|
| Baseline | 3.38 ± 0.402 | 3.34 ± 0.322 |
| Week 2 | 3.39 ± 0.418 | 3.25 ± 0.321 |
| Week 4 | 3.51 ± 0.409 | 3.24 ± 0.317 |
| Week 6 | 3.57 ± 0.412 | 3.2 ± 0.321 |
| Week 8 | 3.61 ± 0.421 | 3.21 ± 0.377 |
| Week 12 | 3.68 ± 0.457 | 3.27 ± 0.295 |
| Week 16 | 3.69 ± 0.44 | 3.29 ± 0.343 |
| Week 19 | 3.67 ± 0.415 | 3.32 ± 0.332 |
| Week 20 | 3.7 ± 0.453 | 3.33 ± 0.318 |
Blood samples were collected to assess reticulocyte count. Baseline was defined as mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated reticulocyte count increased.
| 10^6 cells per microliter | Vadadustat | Placebo |
|---|---|---|
| Baseline | 2.12 ± 0.858 | 1.97 ± 0.816 |
| Week 2 | 0.61 ± 0.778 | -0.07 ± 0.532 |
| Week 4 | 0.29 ± 0.686 | 0.06 ± 0.485 |
| Week 6 | 0.19 ± 0.749 | 0.08 ± 0.549 |
| Week 8 | -0.08 ± 0.737 | 0.06 ± 0.665 |
| Week 12 | -0.12 ± 0.742 | 0.02 ± 0.639 |
| Week 16 | 0.03 ± 0.678 | -0.03 ± 0.659 |
| Week 19 | 0.07 ± 0.88 | -0.05 ± 0.672 |
| Week 20 | 0.03 ± 0.666 | 0.12 ± 0.786 |
Blood samples were collected at indicated time points for analysis of reticulocyte count.
| 10^6 cells per microliter | Vadadustat | Placebo |
|---|---|---|
| Baseline | 2.12 ± 0.858 | 1.97 ± 0.816 |
| Week 2 | 2.74 ± 1.069 | 1.91 ± 0.727 |
| Week 4 | 2.44 ± 0.962 | 2.06 ± 0.731 |
| Week 6 | 2.32 ± 0.996 | 2.07 ± 0.897 |
| Week 8 | 2.05 ± 0.884 | 2.09 ± 0.85 |
| Week 12 | 2.02 ± 0.959 | 2 ± 0.846 |
| Week 16 | 2.13 ± 0.992 | 1.96 ± 0.83 |
| Week 19 | 2.21 ± 1.297 | 1.92 ± 0.77 |
| Week 20 | 2.17 ± 0.954 | 2.1 ± 0.88 |
Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Epoetin Alfa | 4.4 | 12.5 |
| Darbepoetin Alfa | 0 | 4.2 |
Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
| Doses/participants | Vadadustat | Placebo |
|---|---|---|
| Epoetin Alfa | 1.7 ± 1.63 | 2.8 ± 1.79 |
| Darbepoetin Alfa | — | 4.3 ± 2.52 |
Participants were administered packed red blood cell transfusion as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia
| Percentage of participants | Vadadustat | Placebo |
|---|---|---|
| Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue | 0 | 1.4 |
Participants were administered packed red blood cells as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
| Units of blood per participant | Vadadustat | Placebo |
|---|---|---|
| Number of Packed Red Blood Cell Transfusion Administered Per Participant | — | 1.0 (1 to 1) |
Rescue therapy was defined as red blood cell transfusion or ESA administration in participants meeting Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.
| Weeks | Vadadustat | Placebo |
|---|---|---|
| Time to First Transfusion or ESA Rescue Medication Intake | 21.6 ± 6.08 | 21.2 ± 5.71 |
An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.
| Participants | Vadadustat | Placebo |
|---|---|---|
| TEAEs | 58 | 29 |
| Treatment-emergent SAEs | 33 | 11 |
Parameters assessed for laboratory values included hematology, serum chemistry, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat | Placebo |
|---|---|---|
| Hematology | 0 | 0 |
| Serum chemistry | 1 | 0 |
| Urinalysis | 0 | 0 |
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Signs | 0 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.
| Participants | Vadadustat | Placebo |
|---|---|---|
| Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings | 1 | 0 |
A Baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings | 0 | 0 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From the start of treatment (Day 1) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat | 3/138 (2.2%) | 33/138 (23.9%) | 58/138 (42%) |
| Placebo | 0/72 (0%) | 11/72 (15.3%) | 29/72 (40.3%) |
| Event | Vadadustat | Placebo |
|---|---|---|
| RENAL FAILURE ACUTERenal and urinary disorders | 7/138 | 2/72 |
| RENAL FAILURE CHRONICRenal and urinary disorders | 6/138 | 0/72 |
| PNEUMONIAInfections and infestations | 2/138 | 1/72 |
| FLUID OVERLOADMetabolism and nutrition disorders | 2/138 | 1/72 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 2/138 | 0/72 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/138 | 1/72 |
| IRRITABLE BOWEL SYNDROMEGastrointestinal disorders | 0/138 | 1/72 |
| CRYPTOSPORIDIOSIS INFECTIONInfections and infestations | 0/138 | 1/72 |
| GASTROENTERITISInfections and infestations | 0/138 | 1/72 |
| OSTEOMYELITISInfections and infestations | 0/138 | 1/72 |
| Event | Vadadustat | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/138 | 3/72 |
| NauseaGastrointestinal disorders | 14/138 | 3/72 |
| Oedema peripheralGeneral disorders | 10/138 | 7/72 |
| Urinary tract infectionInfections and infestations | 8/138 | 6/72 |
| FatigueGeneral disorders | 11/138 | 5/72 |
| HypertensionVascular disorders | 11/138 | 2/72 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/138 | 5/72 |
| HeadacheNervous system disorders | 8/138 | 2/72 |
| ConstipationGastrointestinal disorders | 5/138 | 4/72 |
| HypotensionVascular disorders | 6/138 | 4/72 |
Intent-to-Treat (ITT) Population: participants who received at least one dose of study medication.
| Age, Continuous(years) | Vadadustat | Placebo | Total |
|---|---|---|---|
| Mean | 66.6 ± 9.97 | 65.9 ± 12.33 | 66.4 ± 10.81 |
| Sex: Female, Male(Participants) | Vadadustat | Placebo | Total |
|---|---|---|---|
| Female | 81 | 34 | 115 |
| Male | 57 | 38 | 95 |
| Race (NIH/OMB)(Participants) | Vadadustat | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 49 | 19 | 68 |
| White | 83 | 49 | 132 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
Plan to share: No
Ran from Jul 2013 to primary completion in Sep 2014, 13 months.
Results were first posted in Jul 2022, 7 years 9 months after primary completion. A results delay was requested in Nov 2014.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 13 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat